Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NANP | Q8TBE9 | 3/20 | 0.61 |
| ▸ | SELL | P14151 | 1/20 | 0.50 |
| ▸ | SELP | P16109 | 1/20 | 0.50 |
| ▸ | MAG | P20916 | 3/20 | 0.47 |
| ▸ | SIGLEC7 | Q9Y286 | 7/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | CD22 | P20273 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8664558 | 0.93 | NANP (0.64) | NANPSELLSELPMAGSIGLEC7 | |
| SCHEMBL442944 | 0.93 | NANP (0.61) | NANPSELLSELPMAGSIGLEC7 | |
| SCHEMBL2190269 | 0.91 | NANP (0.59) | NANPSELLSELPMAGSIGLEC7 | |
| SCHEMBL16416308 | 0.91 | NANP (0.59) | NANPSELLSELPMAGSIGLEC7 | |
| SCHEMBL3808166 | 0.90 | NANP (0.58) | NANPSELLSELPMAGSIGLEC7 | |
| SCHEMBL13125452 | 0.90 | NANP (0.74) | NANPSELLSELPMAGSIGLEC7 | |
| SCHEMBL8489507 | 0.90 | NANP (0.74) | NANPSELLSELPMAGSIGLEC7 | |
| SCHEMBL7066109 | 0.90 | NANP (0.74) | NANPSELLSELPMAGSIGLEC7 | |
| SCHEMBL7263212 | 0.90 | NANP (0.62) | NANPSELLSELPMAGSIGLEC7 | |
| SCHEMBL2742889 | 0.90 | NANP (0.74) | NANPSELLSELPMAGSIGLEC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250149173-A1 | DIAGNOSIS OF COLORECTAL CANCER USING TARGETED QUANTIFICATION OF SITE-SPECIFIC PROTEIN GLYCOSYLATION | VENN BIOSCIENCES CORP (US) | 2025-05-08 | — | — | US | disclosed |
| US-20250019432-A1 | CELL-BINDING PROTEINS AND METHODS OF USE | MABLYTICS, INC. | 2025-01-16 | — | — | US | disclosed |
| EP-4479985-A2 | DIAGNOSIS OF COLORECTAL CANCER USING TARGETED QUANTIFICATION OF SITE-SPECIFIC PROTEIN GLYCOSYLATION | Venn Biosciences Corporation (US) | 2024-12-25 | — | — | EP | disclosed |
| EP-4473314-A2 | BIOMARKERS FOR DIAGNOSING PREECLAMPSIA | Venn Biosciences Corporation (US) | 2024-12-11 | — | — | EP | disclosed |
| EP-4460526-A2 | ANTIBODIES HAVING IMPROVED AFFINITY | Mablytics, Inc. (US) | 2024-11-13 | — | — | EP | disclosed |
| WO-2023154967-A2 | DIAGNOSIS OF COLORECTAL CANCER USING TARGETED QUANTIFICATION OF SITE-SPECIFIC PROTEIN GLYCOSYLATION | VENN BIOSCIENCES CORPORATION (US) | 2023-08-17 | — | — | WO | disclosed |
| WO-2023147601-A2 | BIOMARKERS FOR DIAGNOSING PREECLAMPSIA | VENN BIOSCIENCES CORPORATION (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023133095-A2 | ANTIBODIES HAVING IMPROVED AFFINITY | MABLYTICS, INC. (US) | 2023-07-13 | — | — | WO | disclosed |
| EP-4175720-A2 | CELL-BINDING PROTEINS AND METHODS OF USE | Mablytics, Inc. (US) | 2023-05-10 | — | — | EP | disclosed |
| WO-2022006370-A2 | CELL-BINDING PROTEINS AND METHODS OF USE | MABLYTICS, INC. (US) | 2022-01-06 | — | — | WO | disclosed |
| CN-104334737-A | Method for producing activated sugar-chain derivative, and activated sugar-chain derivative | GLYTECH INC | 2015-02-04 | — | — | CN | disclosed |
| CN-104114186-A | A broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza hemagglutinin | CHILDRENS MEDICAL CENTER | 2014-10-22 | — | — | CN | disclosed |
| US-20100291689-A1 | Lanthanide Complexes as Fluorescent Indicators for Neutral Sugars and Cancer Diagnosis | BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY & AGRICULTURAL AND MECHANICAL COLLEGE (US) | 2010-11-18 | — | — | US | disclosed |
| US-20090074666-A1 | Peptide vaccine for influenza virus | GLYKOS FINLAND OY (FI) | 2009-03-19 | — | — | US | disclosed |
| US-20070243629-A1 | High Affinity Ligands for Influenza Virus and Methods for Their Production | GLYKOS FINLAND OY (FI) | 2007-10-18 | — | — | US | disclosed |
| WO-2007109465-A2 | LANTHANIDE COMPLEXES AS FLUORESCENT INDICATORS FOR NEUTRAL SUGARS AND CANCER DIAGNOSIS | BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY & AGRICULTURAL AND MECHANICAL COLLEGE (US) | 2007-09-27 | — | — | WO | disclosed |
| EP-1680133-A2 | HIGH AFFINITY LIGANDS FOR INFLUENZA VIRUS AND METHODS FOR THEIR PRODUCTION | Glykos Finland Oy (FI) | 2006-07-19 | — | — | EP | disclosed |
| WO-2005037187-A2 | HIGH AFFINITY LIGANDS FOR INFLUENZA VIRUS AND METHODS FOR THEIR PRODUCTION | GLYKOS FINLAND OY (FI) | 2005-04-28 | — | — | WO | disclosed |
| CN-1033031-C | Modified gangliosides and functional derivatives thereof | FIDIA SPA (IT) | 1996-10-16 | — | — | CN | disclosed |
| CN-1051912-A | Improved gangliosides and functional derivatives thereof | FIDIA B P A (IT) | 1991-06-05 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100291689-A1 | Lanthanide Complexes as Fluorescent Indicators for Neutral Sugars and Cancer Diagnosis | LPAR3, LPCAT1, LYPLAL1 | NANP 203/4885SELL 325/4885SELP 369/4885 |
| US-20070243629-A1 | High Affinity Ligands for Influenza Virus and Methods for Their Production | SIGLEC7, NEU3, NEU4 | NANP 111/4885SELL 259/4885SELP 202/4885 |
| US-20090074666-A1 | Peptide vaccine for influenza virus | SIGLEC7, SIGLEC9, NEU3 | NANP 355/4885SELL 303/4885SELP 66/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.